Abstracts tagged "rheumatoid arthritis (RA) and treatment options"

Abstract Number: 94 • 2014 ACR/ARHP Annual Meeting
Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA
Marcia Genta, Dallas Arthritis Center, Dallas, TX
Background/Purpose: Biologics, a relatively new widely used class of medication that can substantially improve the course of RA, are expensive and their use is not…
Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
P.H.P. de Jong¹, J.M.W. Hazes², K.H. Han³, A.M. Huisman⁴, D. van Zeben⁵, P.A. van der Lubbe⁶, A.H. Gerards⁶, B. van Schaeybroeck⁷, P.B. de Sonnaville⁸, M.V. Krugten⁹, J.J. Luime² and A.E.A.M. Weel³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁷Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…
Abstract Number: 1419 • 2013 ACR/ARHP Annual Meeting
Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial
Sofie H.M. Manders¹, Wietske Kievit², Herman L.M. Brus³, Hein J. Bernelot Moens⁴, Andre Hartkamp⁵, Reinhard Bos⁶, Elisabeth Brouwer⁷, Henk Visser⁸, Harald E. Vonkeman⁹, Rene Westhovens¹⁰, Mart A.F.J. van de Laar¹¹ and Piet LCM Van Riel¹, ¹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³TweeSteden Ziekenhuis, Tilburg, Netherlands, ⁴Ziekenhuisgroep Twente, Almelo, Netherlands, ⁵Reumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, ⁶Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Rijnstate, Arnhem, Netherlands, ⁹Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ¹⁰Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ¹¹Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: The best treatment option after a patient has failed a first TNFi is still unknown. Therefore the objective of this randomized open label study…
Abstract Number: 1346 • 2013 ACR/ARHP Annual Meeting
Drug Free Holiday In Patients With Rheumatoid Arthritis (RA): patients’ Opinion
I.M. Markusse, G. Akdemir, T.W.J. Huizinga and C.F. Allaart, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Clinical trials have shown that in many patients tapering and/or stopping antirheumatic medication is a realistic option. We interviewed patients to investigate their opinions,…
Abstract Number: 1050 • 2013 ACR/ARHP Annual Meeting
Population-Based Analysis Of Treatment Patterns For Recently Diagnosed Rheumatoid Arthritis Patients In The United States
Martin M. Crane¹, Boyka Stoykova², Julie Priest¹, Nasha Wang¹, Henry Krzywy¹ and Rahul Ganguly³, ¹WW Epidemiology, GlaxoSmithKline, Durham, NC, ²Global Health Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom, ³Global Health Outcomes, GlaxoSmithKline, Durham, NC
Background/Purpose: As treatment paradigms for rheumatoid arthritis (RA) continue to evolve, population-based studies can help assess which strategies are being used in “real-world” practice for…
Abstract Number: 1722 • 2012 ACR/ARHP Annual Meeting
Exploring How Patients with Rheumatoid Arthritis Use a Methotrexate Decision Aid for Making Treatment Choices
Linda C. Li¹, Anne F. Townsend², Paul M. Adam³, Catherine L. Backman⁴, Sydney Brooks⁵, Gwen A. Ellert⁶, Allyson Jones⁷, Otto Kamensek⁸, Cheryl Koehn⁹, Diane Lacaille⁸, Jenny Leese², Colleen Maloney⁸, Elaine Yacyshyn¹⁰, Charlene Yousefi⁸ and Dawn Stacey¹¹, ¹Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, ⁵The Arthritis Society, Ontario Division, Toronto, ON, Canada, ⁶Health Education, Trelle Enterprises Inc, Vancouver, BC, Canada, ⁷Department of Physical Therapy, University of Alberta, Edmonton, AB, Canada, ⁸Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁹Arthritis Consumer Experts, Vancouver, BC, Canada, ¹⁰562 Heritage Med Rsch Ctr, University of Alberta, Edmonton, AB, Canada, ¹¹School of Nursing, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: For patients with rheumatoid arthritis (RA), making treatment decisions can be overwhelming. The literature describes a sense of ambivalence among patients with chronic diseases…
Abstract Number: L7 • 2012 ACR/ARHP Annual Meeting
Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial
Bruno Fautrel¹, Thao Pham², Florence Tubach³, Toni Alfaiate⁴, Jacques Morel⁵, Emmanuelle Dernis⁶, Xavier J. Puechal⁷, Philippe Gaudin⁸ and Xavier Mariette⁹, ¹Rheumatology, UPMC - Paris 6 University, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Centre Hospitalier, Le Mans, France, ⁷Le Mans Hospital, Le Mans, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: Step-down therapeutic strategies are often considered in established rheumatoid arthritis (RA) once remission is achieved but are associated with a potential risk of relapse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].